Literature DB >> 15655057

Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population.

K Hayashi1, S Hasuike, K Kusumoto, A Ido, H Uto, N Kenji, M Kohara, S O Stuver, H Tsubouchi.   

Abstract

A new immuno-radiometric assay (IRMA) to detect hepatitis C virus (HCV) core antigen (HCVcAg) has been developed. The aim of the present study was to investigate the sensitivity and specificity of this IRMA to measure HCV antigenemia, based on the detection of HCV RNA as the gold standard, and to assess the utility of the IRMA in a community-based population. Anti-HCV positive residents in a hyperendemic area of HCV infection in Japan were studied. Serum levels of HCVcAg were measured using IRMA, and the presence of HCV RNA was determined by a qualitative reverse transcription-polymerase chain reaction (RT-PCR) assay. The sensitivity and the specificity of the IRMA were 96.4 and 100%, respectively. The sensitivity of the IRMA was similar between serological HCV group I (HCV genotypes 1a and 1b) (97.6%) and group II (HCV genotypes 2a and 2b) (94.0%). There was a strong correlation between serum HCVcAg level and HCV-RNA measured by a quantitative RT-PCR (r = 0.832, P < 0.0001). There also was a very strong correlation of HCVcAg level between IRMA measurements performed on serum and those performed on plasma (r = 0.984, P < 0.0001). In conclusion, this new IRMA is useful for the detection of HCV core antigen in a community-based population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655057     DOI: 10.1111/j.1365-2893.2005.00558.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

1.  New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification.

Authors:  Yongjung Park; Jong-Han Lee; Beom Seok Kim; Do Young Kim; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

2.  Is hepatitis C virus core antigen an adequate marker for community screening?

Authors:  Yuan-Hung Kuo; Kuo-Chin Chang; Jing-Houng Wang; Pei-Shan Tsai; Shu-Feng Hung; Chao-Hung Hung; Chien-Hung Chen; Sheng-Nan Lu
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

3.  Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.

Authors:  A Pivert; C Payan; P Morand; S Fafi-Kremer; J Deshayes; F Carrat; S Pol; P Cacoub; C Perronne; F Lunel
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

4.  Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.

Authors:  Yuka Takahama; Hirofumi Uto; Shuji Kanmura; Makoto Oketani; Akio Ido; Kazunori Kusumoto; Satoru Hasuike; Kenji Nagata; Katsuhiro Hayashi; Sherri Stuver; Akihiko Okayama; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

5.  Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.

Authors:  Hirofumi Uto; Joji Kurogi; Yuka Takahama; Kazunori Kusumoto; Katsuhiro Hayashi; Akio Ido; Michinori Kohara; Sherri O Stuver; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

6.  Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.

Authors:  Hirofumi Uto; Sherri O Stuver; Katsuhiro Hayashi; Kotaro Kumagai; Fumisato Sasaki; Shuji Kanmura; Masatsugu Numata; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Akio Ido; Kazunori Kusumoto; Satoru Hasuike; Kenji Nagata; Michinori Kohara; Hirohito Tsubouchi
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

7.  Association of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis.

Authors:  Akihiko Kato; Takako Takita; Mitsuyoshi Furuhashi; Taiki Fujimoto; Hiroo Suzuki; Yukitaka Maruyama; Yukitoshi Sakao; Hiroaki Miyajima
Journal:  Nephron Extra       Date:  2012-03-28

8.  Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.

Authors:  Yuki Wada; Hideyuki Tamai; Akira Kawashima; Naoki Shingaki; Yoshiyuki Mori; Masanori Kawaguchi; Kosaku Moribata; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Masao Ichinose
Journal:  Gut Liver       Date:  2014-04-23       Impact factor: 4.519

9.  Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.

Authors:  Hideyuki Tamai; Naoki Shingaki; Yoshiyuki Mori; Kosaku Moribata; Akira Kawashima; Yoshimasa Maeda; Toru Niwa; Hisanobu Deguchi; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Masao Ichinose
Journal:  Gut Liver       Date:  2016-07-16       Impact factor: 4.519

10.  Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.

Authors:  Mi Na Kim; Hyon Suk Kim; Ja Kyung Kim; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Hyub Han
Journal:  J Korean Med Sci       Date:  2016-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.